Emerging Challenges in Managing Hepatitis B in HIV Patients
- 457 Downloads
Roughly 10 % of HIV-positive individuals worldwide have concomitant chronic hepatitis B virus (HBV) infection, with large differences between geographical regions and/or risk groups. Hepatitis B is a preventable infection with vaccines. However, it cannot be eradicated once acquired, resembling HIV and in contrast with HCV. In developed countries, hepatitis B exhibits particular features in the HIV population. First, HBV infection is less frequently misdiagnosed than in the general population. Second, nucleos(t)ide analogs active against HBV are widely used as part of antiretroviral combinations and are taken by most HIV patients. Lastly, as the HIV population ages given the success of antiretroviral therapy, non-AIDS co-morbidities are becoming a major cause of disease, for which specific drugs are required, increasing the risk of interactions and hepatotoxicity. Furthermore, concern on HBV reactivation is rising as immunosuppressive drug therapies are increasingly been used for cancers and other non-malignant conditions. In this scenario, new challenges are emerging in the management of hepatitis B in HIV-positive individuals. Among them, major interest is focused on failures to suppress HBV replication, HBV breakthroughs and reactivations, the meaning of isolated anti-HBc, screening for liver cancer, and the complexity arising when hepatitis viruses C and/or D are additionally present. This review will focus on these challenges and the major advances in HBV coinfection in HIV.
KeywordsHBV Hepatitis B HIV Coinfection Tenofovir Lamivudine Drug resistance Hepatitis delta Vaccine
Compliance with Ethics Guidelines
Conflict of Interest
Vincent Soriano declares a grant from Instituto de Salud Carlos III for projects ICI14-00372, CES12/003, PI13/01574) and a grant from Fundacion Investigacion y Educacion en SIDA.
Pablo Labarga, Carmen de Mendoza, José M. Peña, José V. Fernández-Montero, Laura Benítez, Isabella Esposito, and Pablo Barreiro declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 6.•WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March 2015 (www.who.int) This document is an updated comprehensive report on the prevention, management and treatment of hepatitis B, with special focus on developing regions. Non-invasive methods for assessing liver fibrosis are overtly recommended instead of liver biopsies whereas tenofovir or entecavir are preferred over lamivudine as HBV therapy.
- 7.•Modi A, Feld J. Viral hepatitis and HIV in Africa. AIDS Rev. 2007;9:25–39. This is one of the most comprehensive reviews on the epidemiology of viral hepatitis in Africa and its overlap with the HIV epidemic.Google Scholar
- 12.European AIDS Clinical Society Guidelines. Version 7.0. October 2013. Available at http://www.europeanaidsclinicalsociety.org. Accessed on April 27th 2015.
- 13.DHHS. Recommendations for use of antiretroviral drugs in HIV-1-infected adults and adolescents. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/.pdf. Accessed on April 27th 2015.
- 15.•Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6. This is a pivotal study demonstrating that HIV worsts the natural history of chronic hepatitis B.Google Scholar
- 16.Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci (in press).Google Scholar
- 17.•Martín-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73–9. This study reports HBV outcomes in one of the largest series of HIV-HBV coinfected individuals followed for the longest follow-up on tenofovir-containing regimens.Google Scholar
- 19.•Boyd A, Gozlan J, Maylin S, et al. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology. 2014;60:497–507. This study reported a 10% rate of low-level HBV-DNA in 111 HIV-HBV coinfected patients treated with tenofovir and followed for more than 6 years.Google Scholar
- 23.Corsa A, Liu Y, Flaherty J, et al. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol (in press).Google Scholar
- 25.Boyd A, Moh R, Gabillard D, et al. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV co-infected patients from Cote d’Ivoire. Antivir Ther 2015 (in press).Google Scholar
- 35.Berg T, Simon K, Mauss S, Schott E, Heyne R, Klass D, et al. Stopping tenofovir treatment after long-term virologic suppression in HBeAg-negative CHB: week 48 interim results from an ongoing randomized, controlled trial (FINITE CHB) [abstract O-119]. J Hepatol. 2015;62(suppl):253.CrossRefGoogle Scholar
- 41.Wands J, Chura C, Roll F, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.Google Scholar
- 42.•Perrillo R, Martin P, Lok A. Preventing hepatitis B reactivation due to immunosuppressive drug regimens. JAMA (in press). This editorial briefly updates which circumstances may prone to hepatitis B reactivation and how to prevent it.Google Scholar
- 44.Seto W, Chan T, Hwang Y, Wong D, Liu K, Gill H, et al. A prospective study of hepatitis B reactivation in patients with prior HBV exposure undergoing hematopoietic stem cell transplantation: reactivation association with graft-versus-host disease [abstract O-009]. J Hepatol. 2015;62(suppl):194.CrossRefGoogle Scholar
- 48.•McMahon B, Jilek B, Brennan T, et al. The HBV drug entecavir—effects on HIV-1 replication and resistance. N Engl J Med. 2007;356:2614–21. This was the first report of the unexpected weak antiretroviral effect of entecavir and the risk for selection of drug resistance mutations in HIV.Google Scholar
- 50.López-Serrano P, de la Fuente E, Carrera E, Pérez-Calle J, Fernández C. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: when and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol. 2015;7:539–47.PubMedCentralPubMedCrossRefGoogle Scholar
- 51.Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of HBV in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556–64.PubMedCrossRefGoogle Scholar
- 55.World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84:405–19.Google Scholar
- 59.Roni D, Pathapati R, Kumar A, Nihal L, Sridhar K, Tumkur RS. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013;20:196704.Google Scholar
- 65.•Chen C, Yang H, Su J, et al. Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. This manuscript derives from the REVEAL-HBV study and reported for the first time a strong positive direct correlation between baseline serum HBV-DNA and the risk of liver cancer in chronic hepatitis B patients.Google Scholar
- 75.•Collins J, Raphael K, Terry C, et al. Hepatitis B reactivation during successful treatment of hepatitis C with sofosbuvir and simeprevir. Clin Infect Dis (in press) This study records for the first time two cases of HBV reactivation during successful DAA therapy for hepatitis C.Google Scholar
- 81.•Fernández-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549–53. This large study highlights the deleterious impact of hepatitis delta on HIV-positive individuals in comparison with coinfection with other hepatitis viruses (B and C).Google Scholar
- 88.Wedemeyer H, Port K, Heidrich S, et al. 96 weeks of pegylated interferon alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. Washington DC: AASLD; 2013 [abstract 31].Google Scholar
- 90.James G, Sidhu P, Raza M. First report of successful clearance of hepatitis B and D coinfection with tenofovir monotherapy. Hepatology (in press).Google Scholar
- 93.Soriano V, Barreiro P, de Mendoza C. Tenofovir for hepatitis delta. Hepatology (in press).Google Scholar
- 100.Pal A, Sarkar N, Saha D, et al. High incidence of lamivudine-resistance associated vaccine-escape HBV mutant among HIV-coinfected patients on prolonged antiretroviral therapy. Antivir Ther (in press).Google Scholar